Brian armstrong, the billionaire founder of the cryptocurrency platform Coinbase, has founded a new "epigenetic reprogramming" company called NewLimit, with the aim of greatly extending human longevity.
Armstrong is partnering with Blake Byers, a Silicon Valley entrepreneur with a PhD in bioengineering from Stanford, to stop aging in its tracks.
Second the official press release, "NewLimit will begin by thoroughly investigating the epigenetic aspects of age and developing treatments to regenerate tissue for certain patient groups," according to a press release.
Artificial intelligence against aging to extend human life
NewLimit claims it will employ machine learning algorithms (what else, what else?) To analyze how human cells change over time. The startup, it reads, "will eventually develop therapies that can slow, stop or reverse this process." Extending human life, the statement reads, is an "extremely ambitious" goal.
And I would say. Reversing the aging process has been a "scientific dream" for decades, but despite countless years of research, there is still no fountain of youth. Despite this, NewLimit is ready to "start today" even though its goal may take "decades to achieve"
Still a billionaire who throws money at death hoping to bring it down
Even the founder of Amazon, Jeff Bezos, is famously investing in anti-aging technologies. The company he is investing in, Altos Labs, seeks to reprogram genes to turn back the biological clock and extend human lifespan.
Others like SpaceX CEO Elon Musk have a radically different opinion. For two days on the Futuroprossimo facebook page The controversy rages on Musk's recent interview with the Wall Street Journal. Musk, Time's newly elected "Person of the Year", says "it's important for us to die because most of the time people don't change their minds, they just die."
What is NewLimit's approach to extending human life?
Rather than trying to repair the damage caused by free radicals, NewLimit believes it is possible to reverse aging by assigning a unique function to new cells.
"Put simply, we want to find a way to restore the regenerative potential we all had when we were younger, but somehow lost," the statement read.
A still embryonic science, no doubt, but this does not prevent very wealthy investors from investing in various assets such as NewLimit. The startup is taking its first steps and has already raised over $ 100 million to get its operations off the ground.
"We expect capital will not be the limiting factor for the next few years," Armstrong and Byers boast in their statement.
